Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023.
Lustig Y, Canetti M, Indenbaum V, Peretz Y, Weiss-Ottolenghi Y, Margalit I, Asraf K, Levin T, Zuckerman N, Tomer E, Mandelboim M, Doolman R, Barda N, Regev-Yochay G. Lustig Y, et al. Among authors: indenbaum v. Emerg Infect Dis. 2024 May;30(5):1050-1052. doi: 10.3201/eid3005.231739. Emerg Infect Dis. 2024. PMID: 38666742 Free PMC article.
Does the SARS-CoV-2 mRNA vaccine and its serum IgG levels affect fertility treatments and obstetric outcomes? An observational cohort study.
Miller ND, Goren Gepstein N, Cohen D, Haikin Herzberger E, Shalev Ram H, Mashiach Friedler J, Sharon Weiner M, Rahav R, Indenbaum V, Lustig Y, Wiser A. Miller ND, et al. Among authors: indenbaum v. Clin Exp Med. 2024 Apr 23;24(1):81. doi: 10.1007/s10238-024-01345-9. Clin Exp Med. 2024. PMID: 38653875 Free PMC article.
Rapid molecular epidemiology investigations into two recent measles outbreaks in Israel detected from October 2023 to January 2024.
Bucris E, Indenbaum V, Levin T, Kanaaneh Y, Friedman K, Kushnir T, Sheffer R, Savion M, Salama M, Di-Castro N, Labay K, Butera M, Shihada B, Mor Z, Lustig Y, Zuckerman NS. Bucris E, et al. Among authors: indenbaum v. Euro Surveill. 2024 Apr;29(16):2400202. doi: 10.2807/1560-7917.ES.2024.29.16.2400202. Euro Surveill. 2024. PMID: 38639095 Free PMC article.
Corrigendum to "Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up" [Clin Microbiol Infect] 29 (7) (2023) 918-923.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abu-Kadar B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Barda N, et al. Among authors: indenbaum v. Clin Microbiol Infect. 2024 Mar;30(3):409-413. doi: 10.1016/j.cmi.2023.12.015. Epub 2023 Dec 19. Clin Microbiol Infect. 2024. PMID: 38128780 Free PMC article. No abstract available.
Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel.
Gilboa M, Gonen T, Barda N, Cohn S, Indenbaum V, Weiss-Ottolenghi Y, Amit S, Asraf K, Joseph G, Levin T, Kanaaneh Y, Aydenzon A, Canetti M, Freedman L, Zuckerman N, Mendelson E, Doolman R, Kreiss Y, Regev-Yochay G, Lustig Y. Gilboa M, et al. Among authors: indenbaum v. JAMA Netw Open. 2023 May 1;6(5):e2314757. doi: 10.1001/jamanetworkopen.2023.14757. JAMA Netw Open. 2023. PMID: 37219906 Free PMC article.
Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, Indenbaum V, Halpern O, Katz-Likvornik S, Levin T, Kanaaneh Y, Asraf K, Amit S, Rubin C, Ziv A, Koren R, Mandelboim M, Tokayer NH, Meltzer L, Doolman R, Mendelson E, Alroy-Preis S, Kreiss Y. Regev-Yochay G, et al. Among authors: indenbaum v. Lancet Microbe. 2023 May;4(5):e309-e318. doi: 10.1016/S2666-5247(23)00012-5. Epub 2023 Mar 21. Lancet Microbe. 2023. PMID: 36963419 Free PMC article.
Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.
Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, Asraf K, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Harats D, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Canetti M, et al. Among authors: indenbaum v. Nat Commun. 2023 Mar 22;14(1):1593. doi: 10.1038/s41467-023-37338-7. Nat Commun. 2023. PMID: 36949080 Free PMC article. No abstract available.
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abd Elkader B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Barda N, et al. Among authors: indenbaum v. Clin Microbiol Infect. 2023 Jul;29(7):918-923. doi: 10.1016/j.cmi.2023.03.007. Epub 2023 Mar 13. Clin Microbiol Infect. 2023. PMID: 36921715 Free PMC article. Clinical Trial.
62 results